OPKO Health (NASDAQ: OPK) Q1 2026 revenue falls as losses narrow and guidance held

Rhea-AI Filing Summary

OPKO Health reported first quarter 2026 results showing lower revenue but narrower losses as it reshapes its business. Total revenue was $124.2 million versus $149.9 million a year earlier, largely reflecting the prior sale of certain BioReference oncology assets.

Operating loss improved to $51.0 million from $67.2 million, and net loss narrowed to $54.8 million, or $0.07 per share, compared with a net loss of $67.6 million, or $0.10 per share. Pharmaceuticals revenue grew to $52.0 million, helped by higher international sales and increased NGENLA profit share, while diagnostics revenue declined to $72.2 million after the oncology divestiture.

Cash, cash equivalents, marketable securities and restricted cash totaled $341.9 million as of March 31, 2026. The company repurchased approximately $92.0 million of stock since its July 2025 authorization, including $4.8 million in the quarter, with about $108.0 million remaining available.

Insights

Biopharma and diagnostics equity analyst

Revenue declined on prior asset sale, but losses narrowed and guidance was reaffirmed.

OPKO Health delivered Q1 2026 revenue of $124.2 million versus $149.9 million in 2025, mainly due to selling certain BioReference oncology assets. Despite the top-line decline, operating loss improved to $51.0 million from $67.2 million, showing cost reductions, especially in diagnostics.

Pharmaceutical revenue rose to $52.0 million, supported by international operations and NGENLA gross profit share of $6.4 million, partly offset by lower BARDA revenue of $4.1 million. Diagnostics services revenue fell to $72.2 million as divested oncology revenue and exited low-margin tests rolled off, while segment operating loss more than halved.

The company ended March 31, 2026 with cash, cash equivalents, marketable securities and restricted cash of $341.9 million and has repurchased $92.0 million of stock under its program. It guided Q2 2026 total revenue to $127–$132 million and reiterated full-year 2026 revenue guidance of $530–$560 million with total costs and expenses of $725–$750 million, indicating a consistent full-year outlook.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

Q1 2026 total revenue: $124.2 million Q1 2026 net loss: $54.8 million Q1 2026 loss per share: $0.07 per share +5 more

8 metrics

Q1 2026 total revenue $124.2 million For the three months ended March 31, 2026; vs. $149.9 million in 2025

Q1 2026 net loss $54.8 million For the three months ended March 31, 2026; vs. $67.6 million in 2025

Q1 2026 loss per share $0.07 per share Basic and diluted; vs. $0.10 per share in 2025 quarter

Cash and equivalents $341.9 million Cash, cash equivalents, marketable securities and restricted cash as of March 31, 2026

Stock repurchases to date $92.0 million Aggregate repurchases under program since July 2025; $4.8 million in Q1 2026

Q2 2026 revenue guidance $127–$132 million Total revenue guidance for the three months ended June 30, 2026

Full-year 2026 revenue guidance $530–$560 million Total revenue guidance for the year ended December 31, 2026

Full-year 2026 costs and expenses $725–$750 million Total costs and expenses guidance; R&D included $125–$135 million

Key Terms

tetravalent bispecific antibody, tetraspecific T-cell engager-expander, in vivo CAR‑T, Biomedical Advanced Research and Development Authority (BARDA), +2 more

6 terms

tetravalent bispecific antibody medical

"MDX2301 is a tetravalent bispecific antibody that neutralizes all known variants"

A tetravalent bispecific antibody is an engineered therapeutic protein that can attach to two different biological targets at the same time and has four binding sites to strengthen those connections. Think of it like a four-pronged connector that can grab two distinct targets more securely than a single hook; that design can improve effectiveness, bring cells or signals together, and reduce dosages. Investors watch this class for its potential to offer stronger clinical benefits, higher development complexity, and distinct competitive or regulatory risks tied to safety and manufacturing.

tetraspecific T-cell engager-expander medical

"MDX2003 (CD19xCD20xCD3xCD28) is a novel tetraspecific T-cell engager-expander"

in vivo CAR‑T medical

"an in vivo CAR‑T and gene delivery platform that it believes is highly differentiated"

Biomedical Advanced Research and Development Authority (BARDA) regulatory

"This trial is being funded by the Biomedical Advanced Research and Development Authority (BARDA)."

A U.S. government agency that funds and supports the development of medical treatments, vaccines, diagnostics and devices for public health emergencies. For investors, BARDA matters because its funding, technical support and procurement commitments can lower a company’s development risk and create a reliable customer, much like a major early backer or anchor buyer that helps turn a risky idea into a viable product and market opportunity.

senior secured royalty financing financial

"Senior secured royalty financing | | 246.6 | | | | 246.4"

Phase 1 clinical trial medical

"Initiated and completed first dose cohort of MDX2301 Phase 1 clinical trial"

A phase 1 clinical trial is the first stage of testing a new drug or treatment in people, typically involving a small group to assess safety, how the body handles the treatment, and appropriate dosing. For investors, phase 1 results are an early risk check — like a test drive that can reveal fatal flaws or promising signals — and they often cause big changes in a drug’s perceived value and the company’s prospects.

Earnings Snapshot

Total revenue: $124.2 million · Guidance included

Q1 2026

Total revenue $124.2 million

Net loss $54.8 million

Loss per share $0.07

Guidance

For Q2 2026, total revenue is guided to $127–$132 million. For full-year 2026, total revenue is guided to $530–$560 million with total costs and expenses of $725–$750 million and R&D of $125–$135 million.

Understanding 8-K Material Events →

0000944809false00009448092026-04-282026-04-28

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 28, 2026

OPKO Health, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-33528	75-2402409
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
4400 Biscayne Blvd.
Miami, Florida				33137
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 305 575-4100

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock		OPK		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On April 28, 2026, OPKO Health, Inc. (the “Company”) issued a press release announcing operating and financial highlights for the quarter ended March 31, 2026. The press release also contains information on how to access the conference call the Company is hosting to provide a business update and discuss its financial and operating results for the first quarter ended March 31, 2026, as well as provide financial guidance. A copy of the press release is attached hereto as Exhibit 99.1.

The information included herein and in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 as amended or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release of the Company dated April 28, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		OPKO Health, Inc.
		By:	/s/ Adam Logal
Date: April 28, 2026		Name:	Adam Logal
		Title:	Senior Vice President, Chief Financial Officer

OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results

Conference call begins at 4:30 p.m. Eastern time today

MIAMI, April 28, 2026 – OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three months ended March 31, 2026.

Highlights from the first quarter of 2026 and recent weeks included the following:

•Initiated and completed first dose cohort of MDX2301 Phase 1 clinical trial for the prevention of COVID-19.MDX2301 is a tetravalent bispecific antibody that neutralizes all known variants of SARS-CoV-2 and also has the potential to delay resistance by emerging variants. The Phase 1 clinical trial (NCT07445971) is evaluating the safety, pharmacokinetics and tolerability of MDX2301 administered via different routes in healthy volunteers and in immune impaired adults at high risk for severe COVID-19. By combining multiple antibody binding domains in a single molecule, MDX2301 is designed to provide high potency and greater breadth compared with conventional monoclonal antibodies. This trial is being funded by the Biomedical Advanced Research and Development Authority (BARDA).

•Initiated MDX2003 Phase 1 clinical trial in relapsed or refractory B-cell lymphoma. MDX2003 (CD19xCD20xCD3xCD28) is a novel tetraspecific T-cell engager-expander designed to optimize sustained T-cell function and address the two most common and validated targets in lymphomas and leukemias. The MDX2003 Phase 1 study (NCT07249905) is designed to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of MDX2003 in adults with various types of B-cell lymphoma. The study includes dose-escalation and dose-expansion phases. B-cell lymphoma, a form of non-Hodgkin lymphoma arising from B lymphocytes, represents the most common lymphoma subtype, accounting for approximately 85% of cases.

•ModeX to present data on multispecific antibody targeted in vivo CAR T cell programs at the American Society of Gene + Cell Therapy (ASGCT) Annual Meeting with plans to enter Phase 1 studies later this year. Built on its multispecific technology, ModeX recently developed an in vivo CAR‑T and gene delivery platform that it believes is highly differentiated compared with ex vivo and other in vivo CAR‑T approaches. Using antibody‑targeted lipid nanoparticles, this platform can deliver genes encoding chimeric antigen receptors (CARs) directly to specific immune cell subsets that generate functional CAR‑T cells in vivo.

•Presented two posters highlighting MDX2003 and MDX2004 at the ESMO Targeted Anticancer Therapies Congress 2026. In March, an abstract titled “MDX2003, a First-in-Class CD19xCD20xCD3xCD28 Tetraspecific T-Cell Engager with Potent Preclinical Activity against B Cell Malignancies and Promise in Autoimmunity” was presented at the European Society for Medical

Oncology’s (ESMO) Targeted Anticancer Therapies Congress 2026 in Paris. An abstract titled “A phase 1/2a, multicenter, first-in-human, open-label clinical trial evaluating monotherapy with MDX2004, a trispecific antibody-fusion protein in patients with advanced tumors” was also presented at the Congress.

•Expanded partnership with Entera Bio to advance first-in-class oral long-acting PTH tablet for patients with hypoparathyroidism. This third program under the collaboration combines OPKO's proprietary long-acting PTH variants with Entera's proprietary N-Tab® technology. Following favorable pharmacodynamic and pharmacokinetic data reported in December 2025, the companies have jointly decided to accelerate development and expect to file an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) in late 2026. OPKO and Entera Bio each hold a 50% ownership interest in the long-acting PTH hypoparathyroidism program and each is responsible for 50% of the program's development costs.

First Quarter Financial Results

•Consolidated: Consolidated total revenues for the first quarter of 2026 were $124.2 million compared with $149.9 million for the 2025 period, with the decrease principally resulting from the sale of certain BioReference assets in 2025. Operating loss for the first quarter of 2026 improved to $51.0 million compared with operating loss of $67.2 million for the 2025 quarter. Net loss for the first quarter of 2026 was $54.8 million, or $0.07 per share, compared with net loss of $67.6 million, or $0.10 per share, for the 2025 quarter. The prior year results included a $3.9 million realized gain from the sale of shares of GeneDx Holdings Corp.

•Pharmaceuticals: Revenue from products in the first quarter of 2026 was $38.0 million compared with $34.8 million in the first quarter of 2025, driven by higher sales volumes from OPKO’s Spanish operations and by a positive net foreign exchange impact of $2.4 million. Revenue from Rayaldee remained consistent at $6.3 million in the first quarter of both 2026 and 2025. Revenue from the transfer of intellectual property and other rose to $14.0 million, up from $12.3 million in 2025. This was highlighted by an increase in gross profit share payments for NGENLA, which totaled $6.4 million compared with $4.5 million in the 2025 quarter. The increase was partially offset by a decrease in revenue recognized under the BARDA contract, which totaled $4.1 million in the first quarter of 2026 compared with $7.0 million for the same period in 2025. Total costs and expenses were $81.7 million in the first quarter of 2026 compared with $81.9 million in the prior-year period. Operating loss narrowed by 15% to $29.7 million in the first quarter of 2026, which included $18.3 million in depreciation and amortization expense, compared with operating loss of $34.8 million in the first quarter of 2025, which included $17.8 million of depreciation and amortization expense.

•Diagnostics: Revenue from services in the first quarter of 2026 was $72.2 million compared with $102.8 million in the prior-year period, which included $25.9 million of revenue related to the oncology assets sold to Labcorp in September 2025. The remaining decrease was principally a result of lower clinical test reimbursement rates as a result of exiting certain higher priced, but lower or negative gross margin test offerings, as well as a slight decrease in overall testing volumes. Total costs and expenses were $85.1 million in the first quarter of 2026 compared with $126.8 million in the first quarter of 2025, which included $31.3 million of costs and expenses related to oncology assets that were sold to Labcorp. Operating loss narrowed by more than 45% to $13.0 million in the first quarter of 2026, which included $3.9 million of depreciation and

amortization expense, compared with operating loss of $23.9 million in the 2025 period, which included $5.7 million of depreciation and amortization expense.

•Cash, cash equivalents, marketable securities and restricted cash: Cash, cash equivalents, marketable securities and restricted cash were $341.9 million as of March 31, 2026. As of March 31, 2026, approximately $92.0 million of OPKO’s common stock had been repurchased under the program since its authorization in July 2025, including $4.8 million in the first quarter of 2026. Approximately $108.0 million remained authorized and available for future repurchases.

Financial Guidance

The table below contains financial guidance for the 2026 second quarter and the unchanged full year financial guidance (in millions):

	For the three months ended June 30, 2026				For the year ended December 31, 2026
	Low		High		Low		High
Revenue:
Services revenue	$ 72		$ 76		$ 300		$ 312
Product revenue	38		42		160		170
IP and other revenue	15		19		70		80
Total revenue	127		132		530		560
Included in revenue
Pfizer gross profit share	6		8		34		37
BARDA	5		7		18		22
Total costs and expenses	180		190		725		750
R&D included in costs and expenses	32		38		125		135

Conference Call and Webcast Information

OPKO’s senior management will provide a business update, discuss first quarter financial results, provide financial guidance and answer questions during a conference call and live audio webcast today beginning at 4:30 p.m. Eastern time. Participants are encouraged to pre-register for the conference call here. Callers who pre-register will receive a unique PIN to gain immediate access to the call and bypass the live operator. Participants may register at any time, including up to and after the call start time. Those unable to pre-register may participate by dialing 833-630-0584 (U.S.) or 412-317-1815 (International). A webcast of the call can also be accessed at OPKO’s Investor Relations page and here.

A telephone replay will be available until March 5, 2026, by dialing 855-669-9658 (U.S.) or 412-317-0088 (International) and providing the passcode 2140261. A webcast replay will be available beginning approximately one hour after the completion of the live conference call here.

About OPKO Health

OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise, and novel and proprietary technologies. For more information, please visit www.opko.com.

Cautionary Statement Regarding Forward Looking Statements

This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including statements regarding expected financial performance and expectations regarding the market for and sales of our products, including whether and when we will complete the clinical studies initiated for each of MDX2301 and MDX2003, and whether final study data will be positive for one or both studies, whether data will support marketing approval, our ability to develop and commercialize each of MDX2301 and MDX2003, whether MDX2301 is capable of effectively preventing COVID-19, whether each of MDX2301 and MDX2003 will be safe and tolerable, or have any impact on the severity of disease, expectations regarding the products, their efficacy and market potential, whether the in vivo CAR‑T and gene delivery platform is highly differentiated and whether we will initiate a Phase 1 trial in connection therewith, whether we will be able to submit Investigational New Drug application for the oral long-acting PTH tablet and the timing of that submission, whether our expanded collaboration with Entera will be successful, whether our product development efforts will be successful and whether the expected benefits of our products will be realized, including whether preclinical data will be indicative of clinical data should any of our preclinical programs progress into clinical development, whether the relationship with our commercial and strategic partners will be successful, whether our commercial and strategic partners will be able to commercialize our products and successfully utilize our technologies, whether we will continue to successfully advance products in our pipeline and whether they can be commercialized, as well as other non-historical statements about our expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in our Annual Reports on Form 10-K filed and to be filed with the Securities and Exchange Commission and under the heading “Risk Factors” in our other filings with the Securities and Exchange Commission, as well as the continuation and success of our relationship with our commercial partners, liquidity issues and the risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.

Contacts:

Alliance Advisors IR

Yvonne Briggs, 310-691-7100

ybriggs@allianceadvisors.com

or

Bruce Voss, 310-691-7100

bvoss@allianceadvisors.com

—Tables to Follow—

OPKO Health, Inc. and Subsidiaries

Summary of Revenues

(in millions)

Unaudited

										For the three months ended March 31,
									2026			2025
Diagnostics revenue
Core diagnostics									$	65.8		$	70.4
4Kscore Test										6.4			6.5
Divested revenue										0.0			25.9
Revenue from services										72.2			102.8
Pharmaceutical revenue
International operations										31.7			28.5
Rayaldee										6.3			6.3
Revenue from products subtotal										38.0			34.8
NGENLA royalty and profit sharing, and cost sharing										6.4			4.5
BARDA										4.1			7.0
Regeneron										0.9			-
Other royalties and milestones										2.6			0.8
Revenue from transfer of intellectual property and other subtotal										14.0			12.3
Total pharmaceutical revenue										52.0			47.1
Total revenues									$	124.2		$	149.9

OPKO Health, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

(in millions)

Unaudited

	As of
	March 31, 2026				December 31, 2025
Assets:
Cash, cash equivalents, and current restricted cash	$	341.9			$	369.1
Accounts receivable, net		79.6				90.3
Inventory, net		64.4				65.8
Other current assets		49.4				56.7
Total current assets		535.3				581.9
In-process research and development and goodwill		677.3				679.3
Other assets		644.2				670.7
Total Assets	$	1,856.8			$	1,931.9
Liabilities and Equity:
Accounts payable	$	44.2			$	41.1
Accrued expenses		83.5				84.4
Other current liabilities		20.7				21.1
Total current liabilities		148.4				146.6
Long-term portion of convertible notes		87.4				85.0
Senior secured royalty financing		246.6				246.4
Deferred tax liabilities, net		114.6				126.3
Other long-term liabilities, principally leases, and lines of credit		55.2				59.6
Total Liabilities		652.2				663.9
Equity		1,204.6				1,268.0
Total Liabilities and Equity	$	1,856.8			$	1,931.9

OPKO Health, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations

(in millions, except share and per share data)

Unaudited

	For the three months ended March 31,
			2026				2025
Revenues
Revenue from services		$	72.2			$	102.8
Revenue from products			38.0				34.8
Revenue from transfer of intellectual property			14.0				12.3
Total revenues			124.2				149.9
Costs and expenses
Cost of service revenues			56.1				84.5
Cost of product revenues			22.3				22.8
Selling, general and administrative			48.6				59.1
Research and development			29.2				30.8
Amortization of intangible assets			19.0				19.9
Total costs and expenses			175.2				217.1
Operating loss			(51.0	)			(67.2	)
Other expense, net			(9.9	)			(6.2	)
Loss before income taxes and investment losses			(60.9	)			(73.4	)
Income tax benefit			6.1				5.8
Net loss before investment losses			(54.8	)			(67.6	)
Loss from investments in investees			(0.0	)			(0.0	)
Net loss		$	(54.8	)		$	(67.6	)
Loss per share, basic and diluted		$	(0.07	)		$	(0.10	)
Weighted average common shares outstanding, basic and diluted			758,876,415				671,577,429

# # #

FAQ

How did OPKO Health (OPK) perform financially in Q1 2026?

OPKO Health reported Q1 2026 revenue of $124.2 million, down from $149.9 million in 2025. Operating loss improved to $51.0 million, and net loss narrowed to $54.8 million, or $0.07 per share, versus $0.10 per share last year.

What were OPKO Health’s diagnostics and pharmaceutical revenues in Q1 2026?

Diagnostics services revenue was $72.2 million, compared with $102.8 million a year earlier, reflecting oncology asset divestiture and exited tests. Pharmaceutical revenue rose to $52.0 million, driven by international product sales and higher NGENLA profit share, partly offset by lower BARDA revenue.

What guidance did OPKO Health (OPK) give for Q2 and full-year 2026?

For Q2 2026, OPKO expects total revenue between $127 million and $132 million. For full-year 2026, it projects total revenue of $530 million to $560 million and total costs and expenses of $725 million to $750 million, with R&D of $125 million to $135 million.

What is OPKO Health’s cash position and share repurchase activity?

As of March 31, 2026, OPKO held $341.9 million in cash, cash equivalents, marketable securities and restricted cash. Since its July 2025 authorization, it repurchased about $92.0 million of common stock, including $4.8 million in Q1 2026, with roughly $108.0 million remaining authorized.

What clinical and pipeline milestones did OPKO Health highlight for Q1 2026?

OPKO initiated and completed the first dose cohort of a Phase 1 trial for MDX2301, started a Phase 1 trial for MDX2003, and advanced its in vivo CAR‑T platform. It also expanded its Entera Bio partnership on an oral long-acting PTH tablet, targeting an IND filing in late 2026.

How did OPKO Health’s diagnostics segment profitability change year over year?

The diagnostics segment’s operating loss narrowed to $13.0 million in Q1 2026 from $23.9 million in Q1 2025. The improvement followed divestiture of oncology assets and exiting certain low or negative margin test offerings, while depreciation and amortization declined to $3.9 million.

Filing Exhibits & Attachments

2 documents

Press Releases

• EX-99.1 EX-99.1 354.2 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 23.3 KB